Prognostic value of metaphase-fluorescence in situ hybridization in follow-up of patients with acute myeloid leukemia in remission

Wael El-Rifai, Tapani Ruutu, Erkki Elonen, Liisa Volin, Sakari Knuutila

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The presence of residual leukemic cells was studied using met aphase- fluorescence in situ hybridization (FISH) in 22 patients with acute myeloid leukemia treated with chemotherapy only or chemotherapy followed by allogeneic bone marrow transplantation. The patients were followed up during their complete remission (CR) for 4 to 108 months (median, 21 months). A total of 88 BM samples was studied. In most of the samples more than 1,000 metaphase cells were analyzed. Residual leukemic cells were detected in 9 of 22 patients (41%). All patients who had an increasing and/or persisting level of abnormal cells in two or more subsequent samples or whose initial samples contained more than 1% of abnormal cells relapsed with one exception, in whom the later subsequent samples showed disappearance of abnormal cells. The time span before the first positive sample seems to be insignificant with regard to the outcome of relapse. Absence or single occurrence of abnormal cells followed by their disappearance was in agreement with CR in all the cases (16 patients). Our results indicate that metaphase-FISH is a reliable tool in the quantitation of residual leukemic cells and provides valuable prognostic information for patients with AML.

Original languageEnglish (US)
Pages (from-to)3330-3334
Number of pages5
JournalBlood
Volume89
Issue number9
StatePublished - May 1 1997
Externally publishedYes

Fingerprint

Chemotherapy
Metaphase
Fluorescence In Situ Hybridization
Acute Myeloid Leukemia
Fluorescence
Bone
Drug Therapy
Homologous Transplantation
Bone Marrow Transplantation
Recurrence

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Prognostic value of metaphase-fluorescence in situ hybridization in follow-up of patients with acute myeloid leukemia in remission. / El-Rifai, Wael; Ruutu, Tapani; Elonen, Erkki; Volin, Liisa; Knuutila, Sakari.

In: Blood, Vol. 89, No. 9, 01.05.1997, p. 3330-3334.

Research output: Contribution to journalArticle

El-Rifai, Wael ; Ruutu, Tapani ; Elonen, Erkki ; Volin, Liisa ; Knuutila, Sakari. / Prognostic value of metaphase-fluorescence in situ hybridization in follow-up of patients with acute myeloid leukemia in remission. In: Blood. 1997 ; Vol. 89, No. 9. pp. 3330-3334.
@article{00249d638faa4130803968f97cdf98a0,
title = "Prognostic value of metaphase-fluorescence in situ hybridization in follow-up of patients with acute myeloid leukemia in remission",
abstract = "The presence of residual leukemic cells was studied using met aphase- fluorescence in situ hybridization (FISH) in 22 patients with acute myeloid leukemia treated with chemotherapy only or chemotherapy followed by allogeneic bone marrow transplantation. The patients were followed up during their complete remission (CR) for 4 to 108 months (median, 21 months). A total of 88 BM samples was studied. In most of the samples more than 1,000 metaphase cells were analyzed. Residual leukemic cells were detected in 9 of 22 patients (41{\%}). All patients who had an increasing and/or persisting level of abnormal cells in two or more subsequent samples or whose initial samples contained more than 1{\%} of abnormal cells relapsed with one exception, in whom the later subsequent samples showed disappearance of abnormal cells. The time span before the first positive sample seems to be insignificant with regard to the outcome of relapse. Absence or single occurrence of abnormal cells followed by their disappearance was in agreement with CR in all the cases (16 patients). Our results indicate that metaphase-FISH is a reliable tool in the quantitation of residual leukemic cells and provides valuable prognostic information for patients with AML.",
author = "Wael El-Rifai and Tapani Ruutu and Erkki Elonen and Liisa Volin and Sakari Knuutila",
year = "1997",
month = "5",
day = "1",
language = "English (US)",
volume = "89",
pages = "3330--3334",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - Prognostic value of metaphase-fluorescence in situ hybridization in follow-up of patients with acute myeloid leukemia in remission

AU - El-Rifai, Wael

AU - Ruutu, Tapani

AU - Elonen, Erkki

AU - Volin, Liisa

AU - Knuutila, Sakari

PY - 1997/5/1

Y1 - 1997/5/1

N2 - The presence of residual leukemic cells was studied using met aphase- fluorescence in situ hybridization (FISH) in 22 patients with acute myeloid leukemia treated with chemotherapy only or chemotherapy followed by allogeneic bone marrow transplantation. The patients were followed up during their complete remission (CR) for 4 to 108 months (median, 21 months). A total of 88 BM samples was studied. In most of the samples more than 1,000 metaphase cells were analyzed. Residual leukemic cells were detected in 9 of 22 patients (41%). All patients who had an increasing and/or persisting level of abnormal cells in two or more subsequent samples or whose initial samples contained more than 1% of abnormal cells relapsed with one exception, in whom the later subsequent samples showed disappearance of abnormal cells. The time span before the first positive sample seems to be insignificant with regard to the outcome of relapse. Absence or single occurrence of abnormal cells followed by their disappearance was in agreement with CR in all the cases (16 patients). Our results indicate that metaphase-FISH is a reliable tool in the quantitation of residual leukemic cells and provides valuable prognostic information for patients with AML.

AB - The presence of residual leukemic cells was studied using met aphase- fluorescence in situ hybridization (FISH) in 22 patients with acute myeloid leukemia treated with chemotherapy only or chemotherapy followed by allogeneic bone marrow transplantation. The patients were followed up during their complete remission (CR) for 4 to 108 months (median, 21 months). A total of 88 BM samples was studied. In most of the samples more than 1,000 metaphase cells were analyzed. Residual leukemic cells were detected in 9 of 22 patients (41%). All patients who had an increasing and/or persisting level of abnormal cells in two or more subsequent samples or whose initial samples contained more than 1% of abnormal cells relapsed with one exception, in whom the later subsequent samples showed disappearance of abnormal cells. The time span before the first positive sample seems to be insignificant with regard to the outcome of relapse. Absence or single occurrence of abnormal cells followed by their disappearance was in agreement with CR in all the cases (16 patients). Our results indicate that metaphase-FISH is a reliable tool in the quantitation of residual leukemic cells and provides valuable prognostic information for patients with AML.

UR - http://www.scopus.com/inward/record.url?scp=0030917739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030917739&partnerID=8YFLogxK

M3 - Article

C2 - 9129039

AN - SCOPUS:0030917739

VL - 89

SP - 3330

EP - 3334

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -